ISSN 1016-5169 | E-ISSN 1308-4488
pdf
Efficacy and Safety of Fenofibrate in Primary Hyperlipidemic Subjects [Turk Kardiyol Dern Ars]
Turk Kardiyol Dern Ars. 2000; 28(2): 121-125

Efficacy and Safety of Fenofibrate in Primary Hyperlipidemic Subjects

Esmeray ACARTÜRK1, Halis DÖRTLEMEZ1, Esmeray ACARTÜRK1, Halis DÖRTLEMEZ1

In order to evaluate the efficacy and safety of fenofibrate in Turkish people, 249 primary hyperlipidemic subjects, aged 31 - 74 years (mean 54±7), were treated with onee-a-day 250 mg controlled release fenofibrate following a lipidlowering diet. The efficacy and safety parameters were measured at baseline, on the 8th and the 12th weeks of therapy. After a treatment of 12 weeks, a decrease by 14.8% (p<0.0001), 13% (pKeywords: Hypercholesterolemia, hypertriglyceridemia, fenofibrate


How to cite this article
Esmeray ACARTÜRK, Halis DÖRTLEMEZ, Esmeray ACARTÜRK, Halis DÖRTLEMEZ. Efficacy and Safety of Fenofibrate in Primary Hyperlipidemic Subjects. Turk Kardiyol Dern Ars. 2000; 28(2): 121-125
Manuscript Language: Turkish


Journal Metrics

Journal Citation Indicator: 0.18
CiteScore: 1.1
Source Normalized Impact
per Paper:
0.22
SCImago Journal Rank: 0.348

Quick Search



Copyright © 2024 Archives of the Turkish Society of Cardiology



Kare Publishing is a subsidiary of Kare Media.